Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 19,431 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Combination Clear all
Completed Phase 4 Interventional

A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination

NCT00335270
View directory record Official record
Conditions
HIV
Interventions
fos-amprenavir calcium, ritonavir, abacavir/lamivudine as Epzicom
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 28, 2026, 10:21 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

NCT03040973
View directory record Official record
Conditions
Advanced Solid Tumors Which Are cMET-dependent
Interventions
Capmatinib, Nazartinib, Gefitinib, Osimertinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 28, 2026, 10:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer

NCT00559429
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2008 · Synced Oct 28, 2026, 10:21 AM EDT
Completed Phase 3 Interventional

Combination Drug Therapy for Patients With Hepatitis C

NCT00001729
View directory record Official record
Conditions
Chronic Hepatitis C, Fibrosis, Hemolytic Anemia
Interventions
Ribavirin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 28, 2026, 10:21 AM EDT
Completed Phase 2 Interventional

Combined Behavioral/Pharmacological Therapy for Insomnia

NCT00044629
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
Cognitive-Behavioral Therapy for Insomnia, zolpidem tartrate (Ambien), Placebo
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
21 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2013 · Synced Oct 28, 2026, 10:21 AM EDT
Terminated Not applicable Interventional Results available

Hemostasis in Kocher-Langenbeck Approaches for Acetabular Surgery Using a Topical Surgical Hemostat (Vitagel)

NCT01230931
View directory record Official record
Conditions
Fracture Fixation, Intra-Articular Fractures, Acetabulum
Interventions
Vitagel, Standard of care
Device · Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 28, 2026, 10:21 AM EDT
Completed Phase 4 Interventional

Tacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil (MMF) Versus Neoral/Sirolimus in Adult, Primary Kidney Transplantation

NCT00681213
View directory record Official record
Conditions
Adult Primary Kidney Transplantation
Interventions
Tacrolimus/Sirolimus, Tacrolimus/MMF, Neoral/Sirolimus
Drug
Lead sponsor
University of Miami
Other
Eligibility
16 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 28, 2026, 10:21 AM EDT
Completed Phase 3 Interventional Results available

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03751124
View directory record Official record
Conditions
Uterine Leiomyoma, Uterine Fibroids
Interventions
Relugolix, Estradiol/norethindrone acetate, Placebo for relugolix, Placebo for E2/NETA
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
72
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 28, 2026, 10:21 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome

NCT06544642
View directory record Official record
Conditions
Healthy Volunteers, Sjögren's Syndrome
Interventions
ASP5502, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 28, 2026, 10:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vestibular Stimulation to Trigger Adipose Loss (VeSTAL) Clinical Trial

NCT03640286
View directory record Official record
Conditions
Obesity
Interventions
VeSTAL
Device
Lead sponsor
Neurovalens Ltd.
Industry
Eligibility
22 Years to 80 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
3
States / cities
La Jolla, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 28, 2026, 10:21 AM EDT
Recruiting Phase 2Phase 3 Interventional

IV vs Epidural Opioids + Epidural Local Anesthetic for Laparotomy Analgesia

NCT06559969
View directory record Official record
Conditions
Laparotomy
Interventions
Intravenous administered opioid, Epidural administered opioid
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 28, 2026, 10:21 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

NCT06305351
View directory record Official record
Conditions
Obesity, Type 2 Diabetes Mellitus (T2DM)
Interventions
K-757 and K-833 QD, K-757 and K-833 BID, Matching placebo to K-757 and K-833 QD, Matching placebo to K-757 and K-833 BID
Drug
Lead sponsor
TriGemX Bio, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 28, 2026, 10:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

NCT00849251
View directory record Official record
Conditions
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
cyclophosphamide, pegylated liposomal doxorubicin hydrochloride, bortezomib, dexamethasone
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 8, 2017 · Synced Oct 28, 2026, 10:21 AM EDT
Recruiting Phase 2 Interventional

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

NCT05789303
View directory record Official record
Conditions
Multiple Myeloma, Relapse Multiple Myeloma
Interventions
Belantamab mafodotin, Carfilzomib, Pomalidomide, Dexamethasone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 28, 2026, 10:21 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly

NCT03373903
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Placebo, BEZ235, BEZ235 plus everolimus (RAD001)
Other · Drug
Lead sponsor
Restorbio Inc.
Industry
Eligibility
65 Years and older
Enrollment
652 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 28, 2026, 10:21 AM EDT
Recruiting Phase 2 Interventional

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

NCT04991103
View directory record Official record
Conditions
Multiple Myeloma, Amyloidosis
Interventions
DaraVRD/DaraVCD
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 28, 2026, 10:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia

NCT05656027
View directory record Official record
Conditions
Presbyopia, Refractive Error, Eye Diseases, Near Vision
Interventions
Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Brimonidine
Drug
Lead sponsor
LENZ Therapeutics, Inc
Other
Eligibility
45 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
25
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 28, 2026, 10:21 AM EDT
Terminated Phase 1 Interventional

An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

NCT03144661
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Esophageal Cancer, Nasopharyngeal Cancer, Ovarian Cancer, Solid Tumors
Interventions
INCB062079
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Birmingham, Alabama • New York, New York • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 28, 2026, 10:21 AM EDT
Not yet recruiting Phase 4 Interventional

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

NCT07048886
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane
Drug
Lead sponsor
Center for Sight Las Vegas
Other
Eligibility
40 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 28, 2026, 10:21 AM EDT
Completed Not applicable Interventional Results available

Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer

NCT00849186
View directory record Official record
Conditions
Kidney Cancer
Interventions
sunitinib malate, neoadjuvant therapy, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2015 · Synced Oct 28, 2026, 10:21 AM EDT
Active, not recruiting Phase 2 Interventional Results available

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

NCT05440786
View directory record Official record
Conditions
Sarcoma, Ewing, Neoplasm Metastasis
Interventions
Abemaciclib, Irinotecan, Temozolomide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
1 Year to 39 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 10:21 AM EDT
Terminated Phase 1 Interventional

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

NCT02203773
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
Interventions
Posaconazole, ABT-199, Decitabine, Azacitidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
60 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
13
States / cities
Duarte, California • Sacramento, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 28, 2026, 10:21 AM EDT
Completed Phase 3 Interventional

A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg

NCT00171405
View directory record Official record
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 28, 2026, 10:21 AM EDT
Completed Not applicable Interventional Results available

Combined Effects of Early Behavioral Intervention and Propranolol on ASD

NCT02428205
View directory record Official record
Conditions
Autism
Interventions
Propranolol, Placebo
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
3 Years to 10 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 28, 2026, 10:21 AM EDT